Our Vision

The role of Praedicare is to de-risk drug development process for pharmaceutical companies.

Praedicare is a Dallas, Texas company, with clients from around the globe, which uses quantitative wet laboratory models, non-linear dynamical systems, non-linear mathematical models, and the mathematics of topology and morphism mapping for drug development. The role of Praedicare is to de-risk drug development process for pharmaceutical companies. Praedicare can be viewed as the client’s pre-clinical drug development and early clinical phases drug development team for higher, for our tools and their quantitative output, but also IP enrichment and development. Praedicare works in the space from lead development and drug candidate confirmation until IND, and then after in design of clinical trails.

Praedicare de-risks the drug development process costs and time, by application of technologies and techniques that have high quantitative forecasting accuracy early during development of later clinical outcomes. Early choice of leads as regards to efficacy and toxicity de-risks early decision-making in terms of which molecules to proceed with to the next stage, and which to let go, thereby reducing both time to decision-making and financial loss. Performance of dose-response studies across the entire response surface for efficacy and toxicity, using our technologies, eliminates dose-finding studies and suboptimal doses in study patients. This de-risks early phase clinical trials by reducing the number of doses to be tested to a single optimal dose for early phase “first in man” and dose ranging studies. Uniquely, since many diseases, especially chronic infections, all cancers, and autoimmune diseases, are treated with combination therapy regimens, the current paradigm of sequential addition of drugs to regimens and testing in patients to create a combination regimen takes decades to complete.

We utilize our pre-clinical platforms to identify drugs to combine a client’s drug with, and to identify the dose-ratios for the combination, to avoid zones of antagonism while choosing zones of synergy. We identify combination regimens most likely to be efficacious and least toxic, in about a year instead of decades. Moreover, we can compare the client’s new drug, and new combination regimen to the standard of care in our platforms, allowing for identification of efficacy rates in standard of care and in the client’s new regimen, and forecasting phase III clinical trial numbers and requirements. Finally, in the current drug development, children’s regimens are rarely designed early due to toxicity concerns. Therefore de facto it takes decades to develop children’s regimens, which are often a “hand-me-down” from adults. Praedicare helps design regimens for children sui generis, in parallel with regimens for adults, during early drug development stages, reducing the duration of development of drug regimens to use in children from decades to a year or slightly longer. Finally, given our concern for drug resistance in cancer and infections, Praedicare has drug-resistance mitigation strategies to be applied during drug development, that allow for prediction of how and what drug-resistance will look like, how to diagnose it, and what to do if that arises, and how to prevent it.